Abstract Library

#3422 Longitudinal copy number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis and follow-up

Introduction: Research on liquid biopsies in neuroendocrine neoplasms (NENs) remains limited, despite the urgent need for new, preferably blood-based, biomarkers. Copy number alterations (CNAs) represent an important type of molecular alteration in NENs and are detectable in cell-free DNA (cfDNA).

Conference:

Presenting Author:

Authors: Mariën L, Boons G, Vandamme T, Lybaert W, Roeyen G,

Keywords: neuroendocrine neoplasm, liquid biopsies, circulating tumor DNA, biomarker, copy number alterations,

#3202 Plasma cell-free DNA from metastatic gastroenteropancreatic neuroendocrine neoplasms contains tumor-associated copy number alterations

Introduction: Recently, tumor-derived molecular alterations were detected in cell-free DNA (cfDNA) from gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) patients. In-depth evaluation of the biomarker potential of cfDNA is warranted, as better blood-based biomarkers are needed for GEP-NENs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Boons G, Vandamme T, Lybaert W, Roeyen G, Rondou T,

Keywords: cell-free DNA, shallow whole-genome sequencing, gastroenteropancreatic neuroendocrine neoplasm, biomarker,

#2902 DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value

Introduction: Estimating prognosis of pancreatic neuroendocrine tumor (PNET) patients remains challenging. Mutation status of DAXX/ATRX/MEN1, histone modification patterns and immunohistochemistry for relevant transcription factors, including PDX1, were recently used to perform subtyping and distinguished two main types, A and B. These subtypes are linked to cell-of-origin and associated with clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Boons G, Vandamme T, Ibrahim J, Schepers A, Roeyen G,

Keywords: Pancreatic Neuroendocrine Tumor, DNA Methylation, Prognostic Biomarker,

#2139 Genome-Wide DNA Methylation Profiling of Pancreatic Neuroendocrine Tumors

Introduction: Frequent inactivation of epigenetic regulators ATRX and DAXX in pancreatic neuroendocrine tumors (PNETs) suggests an important role for epigenetic alterations in tumorigenesis. Few studies have been published regarding differential methylation patterns in PNETs and a thorough analysis of these alterations is currently lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Boons G, Beyens M, Schepers A, Vandamme T, Roeyen G,

Keywords: pancreatic neuroendocrine tumor, DNA methylation,

#203 Liver and Liver-Pancreastransplantation in the Two-stage Treatment of Liver Metastasized Neuroendocrine Tumors of the Pancreas: About Three Cases

Introduction: Although liver transplantation is a valid option in the treatment of metastasized neuroendocrine tumors, it is not promoted because of a donor organ shortage and disappointing results in older series.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Roeyen G, Chapelle T, De Greef K, Francque S, Michielsen P,

Keywords: livertransplantation, neuroendocrine tumor, selection criteria,